New Custom Conjugated APIs – A Targeted Drug Delivery Paradigm Shift

By Joseph Guiles, PhD, Hauser Pharmaceutical Services, Inc.

New research approaches in the pharma/biotech industry are yielding some amazing, innovative therapeutics focused on unmet medical needs. Gone is the “me-too” approach to drug development and the silo-mentality to chemistry and biology – both hallmarks of the industry. New trends in the way pharmaceutical companies approach research now focuses on highly cross-disciplinary types of development such as chemical biology.

These two shifts, in part, are yielding successful commercial results. By mid-2011 the New York Times had reported that twenty innovative medicines that either effectively differentiate themselves from existing drugs, or tackle ailments lacking viable treatments, had won marketing approval according to the Food and Drug Administration.